Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Depreciation and Depletion (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Depreciation and Depletion for 7 consecutive years, with $42000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion rose 90.91% year-over-year to $42000.0, compared with a TTM value of $146000.0 through Dec 2025, up 64.04%, and an annual FY2025 reading of $146000.0, up 64.04% over the prior year.
  • Depreciation and Depletion was $42000.0 for Q4 2025 at Summit Therapeutics, roughly flat from $42000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $99000.0 in Q2 2022 and bottomed at $20000.0 in Q2 2024.
  • Average Depreciation and Depletion over 5 years is $55600.0, with a median of $44000.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion surged 125.71% in 2021, then plummeted 70.0% in 2024.
  • Year by year, Depreciation and Depletion stood at $79000.0 in 2021, then rose by 11.39% to $88000.0 in 2022, then crashed by 65.91% to $30000.0 in 2023, then decreased by 26.67% to $22000.0 in 2024, then soared by 90.91% to $42000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for SMMT at $42000.0 in Q4 2025, $42000.0 in Q3 2025, and $37000.0 in Q2 2025.